Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.19 USD
Change Today -0.53 / -4.99%
Volume 58.7K
SRNE On Other Exchanges
As of 10:02 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $14.30
52 Week Low
10/14/14 - $3.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, including the treatment of chronic cancer pain, as well as developing therapeutic products for other indications, such as immunology and infectious diseases. Its lead product, Cynviloq, is polymeric, albumin-free nanoparticle paclitaxel formulation, approved and marketed in South Korea for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I, Phase II, and Phase III clinical trials, and post-marketing surveillance studies in MBC, NSCLC, ovarian, pancreatic, and bladder cancer. The company is also developing resiniferatoxin, a non-opiate, ultra potent, and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company’s preclinical human therapeutic monoclonal antibodies include human anti- PD-L1 and anti-PD-1 checkpoint inhibitors; antibody drug conjugates; and bispecific antibodies, as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast for adoptive cellular immunotherapies. It has a collaboration agreement with Conkwest Incorporated to generate and develop products for adoptive immunocellular therapy utilizing Neukoplast cells and chimeric antigen receptors; and NantWorks, Inc. to develop anti-cancer immunotherapies. Sorrento Therapeutics, Inc. was founded in 2006 and is headquartered in San Diego, California.

66 Employees
Last Reported Date: 03/16/15
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $291.4K
Compensation as of Fiscal Year 2013.

sorrento therapeutics inc (SRNE) Key Developments

Sorrento Therapeutics, Inc. Announces Positive TRIBECA Registrational Study Results

Sorrento Therapeutics, Inc. announced positive results from recently analyzed pharmacokinetic (PK) data from its TRIBECA (TRIal establishing BioEquivalence between Cynviloq and Albumin-bound paclitaxel) registrational trial. Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the safety data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.

Sorrento Therapeutics, Inc. Announces Management Changes

Sorrento Therapeutics, Inc. announced the appointments of David H. Deming to its Board of Directors and Mark W. Durand as Chief Financial Officer. Mr. Deming replaced Mr. Durand as a member of the Board, who stepped down to assume the role of Chief Financial Officer. In his Board capacity, Mr. Deming will Chair the Audit Committee and be a member of the Compensation Committee. Mr. Durand has nearly 30 years of pharmaceutical industry experience in a variety of leadership roles in finance, business development and general management. Most recently, he was an independent strategic consultant for emerging pharmaceutical firms.

Sorrento Therapeutics, Inc. Announces Three Preclinical Poster Presentations on Cynviloq

Sorrento Therapeutics, Inc. announced that three preclinical abstracts are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies on the reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $10.19 USD -0.53

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies

Industry Analysis


Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.3x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 76.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at